Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportPoster Presentations - Physicians/Scientists/Pharmacists

Complete metabolic tumor response, assessed by 18FDG-PET, after induction chemotherapy in patients (pts) with locally advanced non small cell lung carcinoma (NSCLC) predicts longer time to progression (TTP) and survival (S)

Hendrik Everaert, Denis Schallier, Bart Neyns, Nick Baelde, Marc Meysman, Jacques De Greve, Johan de Mey, Christian Vanhove and Axel Bossuyt
Journal of Nuclear Medicine May 2006, 47 (suppl 1) 472P;
Hendrik Everaert
1Nuclear Medicine, AZ VUB, Brussels, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Denis Schallier
2Oncology, AZ VUB, Brussels, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bart Neyns
2Oncology, AZ VUB, Brussels, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nick Baelde
3Radiology, AZ VUB, Brussels, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marc Meysman
4Pneumology, AZ VUB, Brussels, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jacques De Greve
2Oncology, AZ VUB, Brussels, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Johan de Mey
3Radiology, AZ VUB, Brussels, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christian Vanhove
1Nuclear Medicine, AZ VUB, Brussels, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Axel Bossuyt
1Nuclear Medicine, AZ VUB, Brussels, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Article Information

vol. 47 no. suppl 1 472P

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Published online October 30, 2014.

Copyright & Usage 
Society of Nuclear Medicine, Inc.

Author Information

  1. Hendrik Everaert1,
  2. Denis Schallier2,
  3. Bart Neyns2,
  4. Nick Baelde3,
  5. Marc Meysman4,
  6. Jacques De Greve2,
  7. Johan de Mey3,
  8. Christian Vanhove1 and
  9. Axel Bossuyt1
  1. 1Nuclear Medicine, AZ VUB, Brussels, Belgium
  2. 2Oncology, AZ VUB, Brussels, Belgium
  3. 3Radiology, AZ VUB, Brussels, Belgium
  4. 4Pneumology, AZ VUB, Brussels, Belgium

Statistics from Altmetric.com

Cited By...

  • Citations
  • Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

Article usage

Article usage: November 2014 to April 2025

AbstractFullPdf
Nov 2014100
Jun 2015100
Jul 2015100
Sep 2015500
Nov 2015100
Aug 2016200
Sep 2016300
Oct 2016100
Dec 2016100
Feb 2017100
Apr 2017200
May 2017100
Jun 2017200
Aug 2017100
Sep 2017100
Oct 2017100
Nov 2017200
Dec 2017300
Feb 2018200
Mar 2018100
Aug 2018100
Mar 2019700
May 2019100
Aug 2019400
Jun 2020200
Oct 2020100
Dec 2020100
Jan 2021200
Feb 20211300
Mar 20211000
Apr 20211100
May 2021400
Jun 2021200
Jul 2021400
Aug 2021200
Sep 2021200
Oct 2021200
Nov 2021200
Dec 2021400
Jan 2022200
Feb 2022300
Mar 2022100
Apr 2022100
May 2022200
Jun 2022300
Aug 2022300
Sep 2022200
Oct 2022200
Nov 2022400
Jan 2023200
Mar 2023300
Apr 2023100
May 2023100
Jun 2023400
Jul 2023400
Aug 2023200
Sep 2023400
Oct 2023100
Nov 2023500
Dec 2023200
Jan 2024500
Feb 2024300
Mar 2024200
Apr 2024200
May 20241200
Jun 2024300
Jul 2024100
Aug 2024700
Sep 2024700
Oct 2024500
Nov 2024500
Dec 2024400
Jan 2025200
Feb 2025300
Mar 2025500
Apr 2025300
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 47, Issue suppl 1
May 1, 2006
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Complete metabolic tumor response, assessed by 18FDG-PET, after induction chemotherapy in patients (pts) with locally advanced non small cell lung carcinoma (NSCLC) predicts longer time to progression (TTP) and survival (S)
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Complete metabolic tumor response, assessed by 18FDG-PET, after induction chemotherapy in patients (pts) with locally advanced non small cell lung carcinoma (NSCLC) predicts longer time to progression (TTP) and survival (S)
Hendrik Everaert, Denis Schallier, Bart Neyns, Nick Baelde, Marc Meysman, Jacques De Greve, Johan de Mey, Christian Vanhove, Axel Bossuyt
Journal of Nuclear Medicine May 2006, 47 (suppl 1) 472P;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Complete metabolic tumor response, assessed by 18FDG-PET, after induction chemotherapy in patients (pts) with locally advanced non small cell lung carcinoma (NSCLC) predicts longer time to progression (TTP) and survival (S)
Hendrik Everaert, Denis Schallier, Bart Neyns, Nick Baelde, Marc Meysman, Jacques De Greve, Johan de Mey, Christian Vanhove, Axel Bossuyt
Journal of Nuclear Medicine May 2006, 47 (suppl 1) 472P;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Poster Presentations - Physicians/Scientists/Pharmacists

  • L1-Targeted Cu-67-radioimmunotherapy in combination with immunotherapy for treatment of ovarian cancer metastases
  • Radionuclide impurities of 210Po produced by neutron irradiation of 209Bi for use in targeted alpha-particle radiotherapy
  • Development of a radiolabeled peptide derivative targeting matrix metalloproteinase-2 for imaging tumors
Show more Poster Presentations - Physicians/Scientists/Pharmacists

Oncology Track

  • Dual time point FDG-PET-CT imaging in differentiating benign from malignant lung nodules: Our experience in 119 patients
  • Evaluation of thymic epithelial tumors by FDG PET: Correlation with the World Health Organization classification
  • Radioimmunotherapy in combination with cytoreductive surgery is an effective treatment of peritoneal carcinomatosis of colonic origin
Show more Oncology Track

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire